All Stories

  1. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume
  2. Expanded conventional first trimester screening
  3. Incorporation of dried blood alpha fetoprotein into traditional first trimester Down syndrome screening service
  4. [179-POS]
  5. Cell‐free fetal DNA screening in the USA: a cost analysis of screening strategies
  6. Maternal Serum Screening Markers and Adverse Outcome: A New Perspective
  7. Extrapolation of maternal weight in sequential aneuploidy screening
  8. Maternal serum analytes as predictors of IUGR with different degrees of placental vascular dysfunction
  9. 175: Combined first trimester screening for Down syndrome with nasal bone (NB) is cost advantageous over NIPS in younger advanced maternal age (AMA) patients
  10. 204: Utilization of a 1/1000 cutoff in combined screening for Down syndrome (DS) in younger AMA patients provides cost advantages compared with NIPS
  11. 718: First trimester maternal weight in USA continues to rise
  12. Quality of Nuchal Translucency Measurements Correlates with Broader Aspects of Program Rigor and Culture of Excellence
  13. 573: Extremely high risk of fetal death and severe perinatal complications associated with simultaneously elevated AFP and very low unconjugated estriol
  14. Impact of nuchal translucency credentialing by the FMF, the NTQR or both on screening distributions and performance
  15. First-trimester screening in triplets
  16. 362: Impact of NT credentialing by FMF, NTQR, or both upon screening distributions and performance
  17. 65: First trimester screening in triplets
  18. 780: First trimester dried blood ADAM-12 as a marker for preterm severe pre-eclampsia (PEC) and intrauterine growth restriction (IUGR)
  19. First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay
  20. Undermeasurement of Nuchal Translucencies: Implications for Screening
  21. Screening for Open Neural Tube Defects
  22. 357: Skewed to the left: under-measurement of NT's and implications for screening efficiency
  23. 731: Management of the CVS window in first trimester Down syndrome screening
  24. 732: Gestational age calculation in first trimester screening: using physician supplied GA or converting using fixed CRL chart has minimal impact on variability of MoM values
  25. 737: Impact of smoking on first trimester dried blood free beta HCG and PAPP-A
  26. 570: Weight and ethnicity marker adjustments in twin pregnancy are similar to singleton adjustments in first trimester screening
  27. 592: Evolving trends in first trimester screening utilization: Increased percentage utilization by lower risk patients
  28. First-trimester screening with nasal bone in twins
  29. 581: First trimester detection of trisomies 13/18 when NT availability is limited
  30. 108: First trimester screening with nasal bone in twins
  31. 593: First trimester T13/18 screening using maternal dried blood free Beta hCG, PAPP-A and NT
  32. Genetic Sonography After First-trimester Down Syndrome Screening
  33. Meta-analysis of first trimester Down syndrome screening studies: free β-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol
  34. Genetic sonography after first-trimester Down syndrome screening
  35. Utilization of first trimester screening is heavily skewed to higher risk patients
  36. First trimester down syndrome screening using early biochemistry to allow for an instant risk assessment at the conclusion of U/S exam
  37. Previous aneuploidy does not significantly alter 1st trimester free beta hcg and papp-a in subsequent normal pregnancies
  38. First-trimester maternal serum markers of fetal anomalies
  39. OP01.02: Association of first-trimester nasal bone length with free beta hCG, PAPP-A and nuchal translcuency
  40. P01.05: The effect of ethnicity on first-trimester nasal bone assessment
  41. OP01.31: Incorporation of nasal bone assessment into first-trimester Down syndrome screening with free beta hCG, PAPP-A and nuchal translucency
  42. First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss
  43. Geometric morphometric analysis of shape outlines of the normal and abnormal fetal skull using three-dimensional sonographic multiplanar display
  44. First trimester down syndrome screening: The impact of using total HCG instead of free HCG
  45. First trimester contingency screening for down syndrome using nasal bone assessment
  46. First-trimester screening for trisomy-21 using a simplified method to assess the presence or absence of the fetal nasal bone
  47. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program
  48. Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes
  49. Appropriate terminology for freeβ-hCG
  50. Statistical flaw in SURUSS model
  51. First-Trimester Screening for Trisomies 21 and 18
  52. First-Trimester Screening for Trisomies 21 and 18
  53. Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in Down syndrome risk assessment
  54. Combined first-trimester versus second-trimester serum screening for Down syndrome: A cost analysis
  55. Low first-trimester pregnancy-associated plasma protein-A and Cornelia de Lange syndrome
  56. Frequency and clinical consequences of extremely high maternal serum PAPP-A levels
  57. First trimester screening with free ?-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction
  58. First trimester biochemical screening for Down syndrome: free beta hCG versus intact hCG
  59. Comparison of urinary free beta (hCG) and beta-core (hCG) in prenatal screening for chromosomal abnormalities
  60. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency
  61. Prospective first-trimester screening: Analysis of nuchal translucency and correlation with biochemical markers
  62. Second-trimester detection of trisomy 18 using free-beta HCG and AFP
  63. Maternal urine screening using dried specimen technology: Comparison of free-beta HCG and beta core fragment
  64. Prenatal maternal dried blood screening with α-fetoprotein and free β-human chorionic gonadotropin for open neural tube defect and Down syndrome
  65. First-trimester Down syndrome screening: Free β-human chorionic gonadotropin and pregnancy-associated plasma protein A
  66. Enhanced twin pregnancy detection within an open neural tube defect and down syndrome screening protocol using free-beta hCG and AFP
  67. Reply
  68. Maternal serum Down syndrome screening: Free β-protein is a more effective marker than human chorionic gonadotropin
  69. Measurement of unconjugated estriol by enzyme-linked immunosorbent assay fails to show an association with Down syndrome
  70. Maternal serum Down syndrome screening: Unconjugated estriol is not useful
  71. Reply
  72. Reply
  73. Maternal serum α-fetoprotein screening
  74. Reply
  75. Maternal serum α-fetoprotein screening
  76. Maternal serum α-fetoprotein screening, maternal weight, and detection efficiency